Detalhe da pesquisa
1.
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG).
BMC Cancer
; 23(1): 180, 2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36814222
2.
Predictive value of chromosome 18q11.2-q12.1 loss for benefit from bevacizumab in metastatic colorectal cancer: A post hoc analysis of the randomized phase III-trial AGITG-MAX.
Int J Cancer
; 151(7): 1166-1174, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35489024
3.
A phase 1 safety and bioimaging trial of antibody DS-8895a against EphA2 in patients with advanced or metastatic EphA2 positive cancers.
Invest New Drugs
; 40(4): 747-755, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35404015
4.
Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
Int J Cancer
; 148(4): 1014-1026, 2021 02 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32984952
5.
Circulating tumor DNA dynamics and recurrence risk in patients undergoing curative intent resection of colorectal cancer liver metastases: A prospective cohort study.
PLoS Med
; 18(5): e1003620, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33939694
6.
Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.
Mod Pathol
; 33(3): 483-495, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31471586
7.
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol
; 20(6): 849-861, 2019 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31003911
8.
The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma.
Ann Surg
; 269(3): 520-529, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-29068800
9.
Is there a role for combined anti-PD-1/CTLA-4 checkpoint blockade in the management of advanced biliary tract cancers?
Cancer
; 129(7): 1129-1130, 2023 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36692958
10.
Phase II study of everolimus (RAD001) monotherapy as first-line treatment in advanced biliary tract cancer with biomarker exploration: the RADiChol Study.
Br J Cancer
; 118(7): 966-971, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29527009
11.
Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol
; 18(11): 1467-1482, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28958504
12.
Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.
Lancet Oncol
; 17(12): 1709-1719, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27743922
13.
Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial.
Br J Cancer
; 114(5): 505-9, 2016 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26867157
14.
A Randomized Phase II Study of FOLFOX With or Without the MET Inhibitor Onartuzumab in Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction.
Oncologist
; 21(9): 1085-90, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27401892
15.
Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
Int J Cancer
; 135(3): 731-41, 2014 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24374727
16.
Peritoneal Tumor DNA as a Prognostic Biomarker in Gastric Cancer: A Systematic Review and Meta-Analysis.
JCO Precis Oncol
; 8: e2300546, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38513167
17.
The association of healthcare contact days with physical function and survival in CCTG/AGITG CO.17.
J Natl Cancer Inst
; 2024 Apr 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38656931
18.
First-Line Nivolumab and Relatlimab Plus Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma: The Phase II RELATIVITY-060 Study.
J Clin Oncol
; 42(17): 2080-2093, 2024 Jun 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38723227
19.
BCL-XL inhibitors enhance the apoptotic efficacy of BRAF inhibitors in BRAFV600E colorectal cancer.
Cell Death Dis
; 15(3): 183, 2024 Mar 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38429301
20.
Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials.
Oncologist
; 18(9): 1004-12, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23881988